Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.
Researchers propose a treatment algorithm to clarify treatment options beyond the first line for metastatic urothelial carcinoma of the bladder.
Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder CancerSeptember 21, 2018
BCG shortages did not appear to influence the incidence of radical cystectomy, but evidence of drug rationing was revealed.
Some prostate cancer cells lack androgen receptors, and they proliferate faster than those that express androgen receptors under androgen-deficient conditions.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Gene expression of a biomarker linked to malignancies, found in stromal cells surrounding a tumor — not the tumor cells themselves — appears to prevent the action of checkpoint blockade.
Researchers assess the outcomes of 5517 patients with bladder cancer who underwent radical cystectomy with or without neoadjuvant radiotherapy or chemotherapy.
Previous studies showed that ddMVAC is well tolerated, but how it compares with gemcitabine plus cisplatin in regard to cancer control and survival outcomes requires further investigation.
When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.
Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Recent analyses suggest that lifetime intake and early-life alcohol use may significantly contribute to the development of high-grade prostate cancer.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.
A reanalysis suggested that an instillation of chemotherapy immediately after surgery may benefit all patients with non-muscle-invasive bladder cancer.
Patients in the SEER-Medicare database with stage IV bladder cancer were found to be less likely to receive chemotherapy than similar cohorts in earlier studies.
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
With the advent of minimally invasive surgery programs, robotic-assisted radical cystectomy is becoming a point of interest for bladder cancer.
Any new study of pazopanib or sunitinib must be placed in perspective of the changing treatment landscape and the market entrance of new immunotherapies.
A better understanding of the factors associated with locoregional recurrence and focused adjuvant therapeutic strategies may lead to enhanced oncologic outcomes.
First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate CancerJuly 31, 2018
Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
The effect of age on outcomes in active surveillance is not well reported and requires further study.
Obesity is associated with an increased likelihood of clear cell and possibly chromophobe renal cell carcinoma.
Widowed patients with bladder urothelial carcinoma have the worst 5-year cancer-specific survival rates among unmarried patients.
Some prior evidence has linked increased sugar consumption to cancer development, but its impact on prostate cancer is unknown.
Evidence for the impact of obesity on outcomes for bladder cancer have been conflicting and require further study.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML